Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review

Clin Lung Cancer. 2021 May;22(3):e466-e469. doi: 10.1016/j.cllc.2020.06.017. Epub 2020 Jun 19.
No abstract available

Keywords: Compound mutations; Epithelial growth factor receptor; Non–small-cell lung cancer; Osimertinib; Uncommon mutations.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Acrylamides / administration & dosage*
  • Acrylamides / pharmacology
  • Afatinib / administration & dosage
  • Afatinib / pharmacology
  • Aged
  • Aniline Compounds / administration & dosage*
  • Aniline Compounds / pharmacology
  • Drug Resistance, Neoplasm
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Mutation
  • Protein Kinase Inhibitors / administration & dosage*
  • Protein Kinase Inhibitors / pharmacology
  • Treatment Outcome

Substances

  • Acrylamides
  • Aniline Compounds
  • Protein Kinase Inhibitors
  • osimertinib
  • Afatinib
  • EGFR protein, human
  • ErbB Receptors